TABLE 3.

Susceptibilities of P. aeruginosa isolates to single agents stratified by location and/or source and percentage of nonsusceptible isolates remaining susceptible to ceftolozane-tazobactam^a

Single agent	All patient isolates (n = 1,257)		ICU patient isolates (n = 359, 28.6%)		Non-ICU patient isolates (n = 898, 71.4%)		Respiratory isolates (n = 490, 39.0%)		Nonrespiratory isolates (n = 767, 61.0%)		ICU patient respiratory isolates (n = 156, 12.4%)		ICU patient nonrespiratory isolates (n = 203, 16.1%)		Non-ICU patient respiratory isolates (n = 334, 26.6%)		Non-ICU patient nonrespiratory isolates (n = 564, 44.9%)
	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T	% S	Of non-S, % S to C-T
Ceftolozane-tazobactam	96.6	NA	95.0	NA	97.2	NA	94.7	NA	97.8	NA	92.3	NA	97.0	NA	95.8	NA	98.0	NA
Cefepime	77.0	87.5	71.6	84.3	79.2	89.3	69.6	83.2	81.7	92.1	59.6	81.0	80.8	89.7	74.3	84.9	82.1	93.1
Ceftazidime	77.0	86.2	68.8	83.9	80.3	87.6	70.0	83.0	81.5	89.4	60.3	80.6	75.4	88.0	74.6	84.7	73.7	90.2
Piperacillin-tazobactam	71.8	90.1	63.0	88.0	75.4	91.4	63.1	87.3	77.4	93.1	50.6	85.7	72.4	91.1	68.9	88.5	79.3	94.0
Meropenem	76.0	90.1	69.9	87.0	78.4	91.8	70.4	85.5	79.5	94.3	59.0	82.8	78.3	93.2	75.7	87.7	80.0	94.7
Tobramycin	91.5	83.2	88.0	76.7	92.9	87.5	90.4	74.5	92.2	90.0	84.0	68.0	91.1	88.9	93.4	81.8	92.6	90.5
Ciprofloxacin	72.3	91.1	71.0	87.5	72.8	92.6	68.0	88.5	75.1	93.2	64.7	83.6	75.9	91.8	69.5	91.2	74.8	93.7

^aDefinitions: C-T, ceftolozane-tazobactam; NA, not applicable; S, susceptible.